Brokerages Set Oxford Immunotec Global PLC (NASDAQ:OXFD) PT at $20.00

Oxford Immunotec Global PLC (NASDAQ:OXFD) has earned a consensus rating of “Hold” from the six brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $19.00.

A number of research firms have recently commented on OXFD. TheStreet lowered Oxford Immunotec Global from a “c-” rating to a “d+” rating in a research report on Monday, July 15th. ValuEngine raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Wednesday, September 25th. Piper Jaffray Companies set a $20.00 price target on Oxford Immunotec Global and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Cowen set a $20.00 price target on Oxford Immunotec Global and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Finally, Zacks Investment Research raised Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research report on Thursday.

In related news, CEO Peter Wrighton-Smith sold 30,000 shares of Oxford Immunotec Global stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $16.21, for a total value of $486,300.00. Following the sale, the chief executive officer now owns 294,538 shares of the company’s stock, valued at approximately $4,774,460.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $19.90, for a total value of $59,700.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 63,000 shares of company stock worth $983,000. 4.21% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP acquired a new stake in Oxford Immunotec Global in the 2nd quarter valued at approximately $173,000. Jane Street Group LLC acquired a new stake in Oxford Immunotec Global in the 2nd quarter valued at approximately $557,000. Morgan Stanley raised its position in Oxford Immunotec Global by 53.2% in the 2nd quarter. Morgan Stanley now owns 508,108 shares of the company’s stock valued at $6,991,000 after buying an additional 176,377 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Oxford Immunotec Global in the 2nd quarter valued at approximately $805,000. Finally, JPMorgan Chase & Co. raised its position in Oxford Immunotec Global by 3.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 94,354 shares of the company’s stock valued at $1,298,000 after buying an additional 3,157 shares during the last quarter. 94.09% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:OXFD traded down $0.07 during mid-day trading on Monday, hitting $14.93. The company had a trading volume of 7,151 shares, compared to its average volume of 188,678. Oxford Immunotec Global has a fifty-two week low of $11.88 and a fifty-two week high of $18.60. The business’s fifty day moving average is $14.99 and its two-hundred day moving average is $14.58. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.76 and a current ratio of 13.35. The firm has a market cap of $405.41 million, a P/E ratio of 29.29 and a beta of 0.43.

Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.07. The firm had revenue of $19.60 million for the quarter, compared to analyst estimates of $19.32 million. Oxford Immunotec Global had a return on equity of 14.76% and a net margin of 208.48%. The company’s quarterly revenue was up 17.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. Equities analysts forecast that Oxford Immunotec Global will post -0.17 earnings per share for the current year.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Read More: What is the Bid-Ask Spread?

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.